Medicenna Therapeutics Corp. completes public offering of units

Date Closed

October 17, 2019

Lead Office

Québec City

Value

6.90 Million CAD

On October 17, 2019, Medicenna Therapeutics Corp. announced the completion of its public offering of 5,307,693 units, including 692,307 units issued upon full exercise of the agents' over-allotment option. At a price of C$1.30 per unit, the total gross proceeds from this offering were approximately C$6.9 million.

Each unit is comprised of one common share of Medicenna and one-half of one common share purchase warrant of Medicenna. The company will use the proceeds from this offering to fund preparations for meetings with regulatory agencies, development of its main immunotherapy products, and general corporate purposes.

Medicenna is a clinical stage immunotherapy company focused on oncology and the development and commercialization of new cancer treatments.

McCarthy Tétrault advised Medicenna with a team led by Charles-Antoine Soulière, Alexandre Saulnier-Marceau, and Annie Poirier-Simard (Securities), and Marie-Soleil Landry and Quentin Lageix (Tax).

People